Chris Chen, PhD WuXi Biologics

Dr. Chris Chen is currently CEO at WuXi Biologics, leading 1200-member biologics service business in China. At WuXi he has built a world-class open-access integrated mab discovery, development and manufacturing platform to service needs from global clients. Under his leadership, Wuxi became the first company in China to build capabilities to develop fully human mabs, the first company to complete IND-enabling CMC package for mabs for global registration, first company to successfully build a cGMP biologics manufacturing facility, the first company to develop novel Antibody Drug Conjugate for global client in China and the first company to supply biologics drug substance and sterile drug product to US clinical trials. He obtained his dual bachelor degrees of chemical engineering and automation at Tsinghua University, Beijing China and his Ph.D. in chemical engineering at the University of Delaware, US. He then gained valuable experience in process development, manufacturing, technology transfer, process validation, quality, and regulatory in the US, where his previous assignments include director and manager positions of bioprocess development, technical service, and pilot plant operations at Lilly and Merck. He later joined Shanghai Celgen Biopharmaceuticals as Chief Operating Officer, successfully developed a high-titer high-quality commercial process for biosimilar Enbrel, and obtained regulatory approval for the program in China. The biosimilar Enbrel was launched in China Sept 2011. In 2009, he co-founded Shanghai Kanda Biotechnology Co Ltd and served as Chief Executive Officer. In two years Kanda became a leading mab CRO/CMO provider in China, successfully completing two Chinese IND-enabling CMC projects on behalf of clients. He is proficient at mab development strategy, high titer cell culture development, large-scale mammalian cell culture, and regulatory and quality of mab manufacturing. Overall he has participated in developing 11 mab programs in US and another 20+ in China. He chaired multiple conferences in biochemical engineering and mab development in US and China and is frequently invited to speak at multiple conferences. He is also adjunct professor at Shanghai Jiaotong University.